相关实验视频

Updated: Jan 16, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

干扰素签名预测急性髓性白血病的化疗耐药性

Ela Cerovska¹, David Kundrat², Zdenek Krejcik²

¹Institute of Hematology and Blood Transfusion, U Nemocnice 2094/1, Prague 128 00, Czech Republic; Faculty of Science, Charles University, Albertov 6, Prague 128 00, Czech Republic.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|October 2, 2025

概括

一个新的IRDS得分预测了急性髓性白血病 (AML) 的化学抵抗. 该工具使用与干扰素相关的DNA损伤抵抗特征 (IRDS) 基因表达来指导AML治疗决策,并确定需要强化治疗的患者.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一种遗传学.

背景情况:

人类循环素-赛塔拉宾诱导仍然是急性髓性白血病 (AML) 治疗的标准.
缺乏AML治疗敏感性的预测标志物.
这项研究旨在开发AML化学抵抗的预测模型.

研究的目的:

开发和验证急性髓性白血病 (AML) 化学抵抗的预测模型.
确定可靠的生物标志物来评估治疗敏感性和指导治疗调整.
帮助选择患者进行强化或实验性AML治疗.

主要方法:

对白血病爆发的转录组测序和DNA甲基化分析.
在响应和不响应患者之间识别差异表达和甲基化基因.
开发和验证一个逻辑回归名录模型来预测完全缓解 (CR).

主要成果:

没有反应的患者显示了与干扰素相关的DNA损伤抵抗特征 (IRDS) 基因的显著过度表达.
基于三个IRDS基因 (IFIT5,IFI44L,IFI44) 的IRDS评分准确预测了CR概率.
成功的治疗反应与治疗后的基因组和染色质重塑基因下调有关.

结论:

基于IRDS得分的模型提供了一个非常准确和可行的方法来预测AML化学抵抗.
这种工具是快速的,具有成本效益,并利用易于获得的生物材料.
IRDS评分可以指导治疗决策,并确定强化或实验性AML治疗的候选人.

关键词:

在急性髓性白血病中,化学抗药性化学抗药性是一种抗药性.基因表达签名基因表达签名通过干扰素刺激的基因.预测性的生物标志物

更多相关视频

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...